Company Overview of Selecta Biosciences, Inc.
Selecta Biosciences, Inc., a clinical-stage biotechnology company, develops targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. The company focus is on developing and commercializing differentiated therapies that are designed to modulate the immune system to effectively and safely treat rare diseases by mitigating the formation of anti-drug antibodies in response to life-sustaining biologic drugs. Its lead product candidate is SEL-212 for the treatment of refractory and chronic tophaceous gout. The company serves customers in the United States and internationally. Selecta Biosciences, Inc. was fo...
480 Arsenal Street
Watertown, MA 02472
Founded in 2007
Key Executives for Selecta Biosciences, Inc.
Chairman, Chief Executive Officer and President
Total Annual Compensation: $400.0K
Chief Medical Officer
Total Annual Compensation: $143.2K
Chief Scientific Officer
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2015.
Selecta Biosciences, Inc. Key Developments
Selecta Biosciences, Inc. Presents at Canaccord Genuity Rare Disease Biopharma 1x1 Day, Feb-07-2017
Jan 31 17
Selecta Biosciences, Inc. Presents at Canaccord Genuity Rare Disease Biopharma 1x1 Day, Feb-07-2017 . Venue: InterContinental Barclay, New York, New York, United States.
Selecta Biosciences, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-16-2017 09:00 AM
Jan 31 17
Selecta Biosciences, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-16-2017 09:00 AM. Venue: Lotte New York Palace, 455 Madison Ave., New York, New York, United States.
Selecta Biosciences, Inc. Announces Data from the Company's Phase 1 Company-Sponsored Trial
Dec 7 16
On December 7, 2016, Selecta Biosciences, Inc. announced data from the Company's Phase 1 company-sponsored trial which assessed single ascending dose safety, pharmacokinetic and pharmacodynamics of SEL-212 in patients with elevated uric acid levels. The Phase 1a trial enrolled 22 U.S. patients with hyperuricemia (uric acid level of >6mg/dL) and evaluated the effect of a single intravenous infusion in a range of 0.1 to 1.2 mg/kg of pegsiticase administered alone. Pegsiticase was generally well tolerated at all tested dose levels. Serum uric acid levels for all patients initially dropped to less than 0.1 mg/dL within approximately 10 hours. However, these levels began rebounding by 14 to 21 days after dosing in a majority of patients. The loss of uric acid level control (defined as uric acid of >6 mg/dL) correlated with the formation of anti-drug antibodies (ADAs). The 0.4 mg/kg dose of pegsiticase was selected as the dose level to carry forward into the Phase 1b trial. The multicenter Phase 1b trial enrolled 63 U.S. patients. One group received a single intravenous infusion of 0.4 mg/kg of pegsiticase alone. Four groups received either placebo or a single intravenous infusion of SVP-Rapamycin alone in a range of 0.03 to 0.5 mg/kg. As expected, SVP-Rapamycin alone did not significantly affect uric acid levels in these patients. Two serious adverse events (SAEs) of stomatitis were observed at the higher dose level tested (0.5 mg/kg), leading the Company to set 0.3 mg/kg as the maximum tolerated dose of SVP-Rapamycin for the Phase 1b trial. All SAEs resolved completely during the study period. Four additional groups in the Phase 1b trial received a single fixed dose of 0.4 mg/kg dose of pegsiticase by intravenous infusion in combination with 0.03, 0.1, 0.15 or 0.3 mg/kg of SVP-Rapamycin: At the 0.03 mg/kg dose, serum uric acid levels were controlled for at least 21 days in four of the five patients. At the 0.1 mg/kg dose, serum uric acid levels were controlled through Day 30 in seven of 10 patients. At the 0.15 mg/kg dose, serum uric acid levels were controlled through Day 30 in all five patients. At the 0.3 mg/kg dose, serum uric acid levels were controlled through Day 30 in all five patients. The substantial and sustained reduction in uric acid levels through at least Day 30 was correlated with the prevention of ADAs. These data supported a monthly dosing regimen in the ongoing multi-dose Phase 2 clinical trial.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 2, 2016